Science Explorer Back to mapMap
Discussion
Researcher · Gazi University · Türkiye

Zübeyde Nur Özkurt

Zübeyde Nur Özkurt publishes mostly in Hematology, Oncology and Genetics, on topics such as Hematopoietic Stem Cell Transplantation, Multiple Myeloma Research and Treatments and Acute Myeloid Leukemia Research.

ORCID 0000-0001-9834-6058 OpenAlex
World rank
#7,661,858
of 7,710,434 ranked researchers
Rank in Türkiye
#115,932
of 117,622
Works
159
Citations
1.2k
Citations per work
7.7
h-index
20
i10-index 37Top 24% in Hematology
Zübeyde Nur Özkurt

What does Zübeyde Nur Özkurt research?

Zübeyde Nur Özkurt's work is mostly in Medicine (57%), Immunology and Microbiology (5%).

Health Sciences: 91 works · 57.2% of their workMedicine: 91 works · 57.2% of their workHematology: 41 works · 26.0% of their workOncology: 21 works · 13.2% of their workGenetics: 11 works · 7.0% of their workEpidemiology: 10 works · 6.6% of their workPathology and Forensic Medicine: 7 works · 4.4% of their workEverything else: 61 works · 38.2% of their workLife Sciences: 7 works · 4.6% of their workImmunology and Microbiology: 7 works · 4.6% of their workImmunology: 7 works · 4.6% of their workTHEIR WORKZübeyde NurÖzkurt159works
Life Sciences5%Health Sciences57%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine9157.2%
  2. Everything else6138.2%
    1. Immunology and Microbiology74.6%
  1. 1Hematology26% of their works
  2. 2Oncology13% of their works
  3. 3Genetics7% of their works
  4. 4Epidemiology7% of their works
  5. 5Immunology5% of their works
  6. 6Pathology and Forensic Medicine4% of their works

Research topics

Which keywords describe Zübeyde Nur Özkurt's research?

The keywords of their largest research topics: Hematopoietic Stem Cells, Prognostic Factors, Bone Marrow Niche, Graft-versus-Host Disease, Minimal Residual Disease, Rituximab, Diagnosis Criteria and International Myeloma Working Group.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Hematopoietic Stem Cells642 topics
  2. Prognostic Factors503 topics
  3. Bone Marrow Niche421 topic
  4. Graft-versus-Host Disease421 topic
  5. Minimal Residual Disease382 topics
  6. Rituximab262 topics
  7. Diagnosis Criteria231 topic
  8. International Myeloma Working Group231 topic
  9. AML221 topic
  10. Acute Myeloid Leukemia221 topic
  11. Acute Lymphoblastic Leukemia151 topic
  12. Antimicrobial Agents151 topic
  13. Childhood Cancer151 topic
  14. Febrile Neutropenia151 topic
  15. BCR-ABL131 topic
  16. Chronic Lymphocytic Leukemia131 topic
  17. Classification131 topic
  18. Genomic Aberrations131 topic
  19. Imatinib131 topic
  20. Lymphoma131 topic

Where does Zübeyde Nur Özkurt work?

Zübeyde Nur Özkurt's main affiliation in the publication record is Gazi University, Türkiye.

How many publications and citations does Zübeyde Nur Özkurt have?

OpenAlex counts 159 works and 1,230 citations for Zübeyde Nur Özkurt, an h-index of 20, ranking #7,661,858 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Zübeyde Nur Özkurt. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.